Market closedNon-fractional

Tarsus Pharmaceuticals/TARS

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Ticker

TARS

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Irvine, United States

Employees

244

TARS Metrics

BasicAdvanced
$1B
Market cap
-
P/E ratio
-$4.70
EPS
1.11
Beta
-
Dividend rate
$1B
1.11
8.012
7.757
11.46
11.46
-42.77%
-34.77%
-66.07%
20.41
3.76
3.81
-6.26
53.22%
88.03%
8.38%
50.81%

What the Analysts think about TARS

Analyst Ratings

Majority rating from 9 analysts.
Buy

TARS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-129.34% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$28M
112.31%
Net income
-$36M
-14.80%
Profit margin
-129.34%
-59.87%

TARS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.17%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.17
-$1.28
-$1.31
-$1.01
-
Expected
-$1.08
-$1.37
-$1.36
-$1.20
-$0.93
Surprise
8.48%
-6.26%
-3.86%
-16.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Tarsus Pharmaceuticals stock?

Tarsus Pharmaceuticals (TARS) has a market cap of $1B as of July 05, 2024.

What is the P/E ratio for Tarsus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Tarsus Pharmaceuticals (TARS) stock is 0 as of July 05, 2024.

Does Tarsus Pharmaceuticals stock pay dividends?

No, Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Tarsus Pharmaceuticals dividend payment date?

Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders.

What is the beta indicator for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (TARS) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Tarsus Pharmaceuticals stock

Buy or sell Tarsus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing